Publications 2017

Xiao Z, Gaertner S, Morresi-Hauf A, Genzel R, Duell T, Ullrich A, Knyazev PG. (2017), Metformin Triggers Autophagy to Attenuate Drug-Induced Apoptosis in NSCLC Cells, with Minor Effects on Tumors of Diabetic Patients, Neoplasia. 19(5):385-395

Orfi Z, Waczek F, Baska F, Szabadkai I, Torka R, Hartmann J, Orfi L, Ullrich A. (2017), Novel members of quinoline compound family enhance insulin secretion in RIN-5AH beta cells and in rat pancreatic islet microtissue, Sci Rep. 7:44073 

Publications 2016

Sommer AK, Hermawan A, Mickler FM, Ljepoja B, Knyazev P, Bräuchle C, Ullrich A, Wagner E, Roidl A. (2016), Salinomycin co-treatment enhances tamoxifen cytotoxicity in luminal A breast tumor cells by facilitating lysosomal degradation of receptor tyrosine kinases, Oncotarget 7(31):50461-50476

Ulaganathan VK, Ullrich A. (2016), Membrane-proximal binding of STAT3 revealed by cancer-associated receptor variants, Mol Cell Oncol 3(3):e1145176

Onken J, Torka R, Korsing S, Radke J, Krementeskaia I, Nieminen M, Bai X, Ullrich A, Heppner F, Vajkoczy P. (2016), Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo, Oncotarget 7(9):9876-89

Simon-Szabó L, Kokas M, Greff Z, Boros S, Bánhegyi P, Zsákai L, Szántai-Kis C, Vantus T, Mandl J, Bánhegyi G, Vályi-Nagy I, Őrfi L, Ullrich A, Csala M, Kéri G. (2016), Novel compounds reducing IRS-1 serine phosphorylation for treatment of diabetes, Bioorg Med Chem Lett. 26(2):424-8

Publications 2015

Ulaganathan VK, Sperl B, Rapp UR, Ullrich A. (2015), Germline variant FGFR4  p.G388R exposes a membrane-proximal STAT3 binding site, Nature 528(7583):570-4

Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, Li J, Shehadeh LA, Hare JM, David V, Martin A, Fornoni A, Di Marco GS, Kentrup D, Reuter S, Mayer AB, Pavenstädt H, Stypmann J, Kuhn C, Hille S, Frey N, Leifheit-Nestler M, Richter B, Haffner D, Abraham R, Bange J, Sperl B, Ullrich A, Brand M, Wolf M, Faul C. (2015), Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy, Cell Metab 22(6):1020-32

Gusenbauer S, Zanucco E, Knyazev P, Ullrich A. (2015), Erk2 but not Erk1 regulates crosstalk between Met and EGFR in squamous cell carcinoma cell lines, Mol Cancer 14:54

Stampolidis P, Ullrich A, Iacobelli S. (2015), LGALS3BP, lectin galactoside-binding soluble 3 binding protein, promotes oncogenic cellular events impeded by antibody intervention, Oncogene 34(1):39-52

Publications 2014

Pénzes K., Baumann C., Szabadkai I., Orfi L., Kéri G., Ullrich A., Torka R. (2014), Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells, Cancer Biol Ther 15(11),1571-82

Xiao Z., Sperl B., Ullrich A., Knyazev P. (2014), Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 status, Oncotarget 5(24):12877-90

Zanucco E., El-Nikhely N., Götz R., Weidmann K., Pfeiffer V., Savai R., Seeger W., Ullrich A., Rapp UR. (2014), Elimination of B-RAF in oncogenic C-RAF-expressing Alveolar epithelial type II cells reduces MAPK signal intensity and Lung Tumor Growth, J Biol Chem 289, 26804-16

Ataseven B., Gunesch A., Eiermann W., Kates RE., Högel B., Knyazev P., Ullrich A., and Harbeck N. (2014), PTK7 as potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients and resistance to anthracycline drugs, Onco Targets Ther 7, 1723-31

Szokol B., Gyulavári P., Kurkó I., Baska F., Szántai-Kis C., Greff Z., Örfi Z., Peták I., Pénzes K., Torka R., Ullrich A., Örfi L., Vántus T., Kéri G. (2014), Discovery and biological evaluation of novel dual EGFR/c-met inhibitors, ACS Med Chem 5, 298-303

Torka R., Penzes K., Gusenbauer S., Baumann C., Szabadkai I., Örfi Z., Kéri G., Ullrich A. (2014), Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy, Neoplasia 16, 301-18

Ho HK., Chua BT., Wong W., Lim KS., Teo V., Ong HT., Chen X., Zhang W., Hui KM., Go ML., Ullrich A. (2014), Benzylidene-indolinones are effective as multi-targeted kinase inhibitor therapeutics against hepatocellular carcinoma, Mol Oncol  7, 1266-77

Baska F., Szabadkai I., Sipos A., Szántai-Kis C., Garamvölgyi R., Nemes Z., Baska F., Neumann L., Torka R., Ullrich A., Kéri G., Örfi L. (2014), Pharmacophore and binding analysis of known and novel B-RAF kinase inhibitors, Curr Med Chem 21, 1938-55 

Paolino M., Choidas A., Wallner S., Pranjic B., Uribesalgo I., Loeser S., Jamieson A., Langdon W., Ikeda F., Fededa J., Cronin S., Nitsch R., Schultz-Fademrecht C., Eickhoff J., Menninger S., Unger A., Torka R., Gruber T., Hinterleitner R., Baier G., Wolf D., Ullrich A., Klebl B., and Penninger J. (2014), The E3 Ligase Cbl-b and TAM receptors regulate cancer metastasis by inhibiting via natural killer cells, Nature 507, 508-12

Tan DS, Haaland B, Gan JM, Tham SC, Sinha I, Tan EH, Lim KH, Takano A, Krisna SS, Thu MM, Liew HP, Ullrich A, Lim WT, Chua BT. (2014), Bosutinib inhibits migration and invasion via ACK1 in KRAS mutant non-small cell lung cancer, Mol Cancer 13:13

Gärtner S, Gunesch A, Knyazeva T, Wolf P, Högel B, Eiermann W, Ullrich A, Knyazev P, Ataseven B. (2014), PTK 7 is a transforming gene and prognostic marker for breast cancer and nodal metastasis involvement, PLoS One 9(1):e84472

Publications 2013

Ho HK., Németh G., Ng YR., Pang E., Szántai-Kris C., Zsákai L., Breza N., Greff Z., Horváth Z., Pató J., Szabadkai I., Szokol B., Baska F., Őrfî L., Ullrich A., Kéri G. and Chua BT. (2013), Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing, Curr Med Chem 20, 1203-17

Vlaicu P., Mertins P., Mayr T., Widschendter P., Ataseven B., Högel B., Eiermann W., Knyazev P., and Ullrich A. (2013), Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator, BMC Cancer

Kaneta Y., and Ullrich A. (2013), NEK9 depletion induces catastrophic mitosis by impairment of mitotic checkpoint control and spindle dynamics, BBRC 442, 139-46

Ezzat S., Zheng L., Florez JC., Stefan N., Mayr T., Hliang MM., Jablonski K., Harden M., Stančáková A., Laakso M., Häring HU., Ullrich A., and Asa SL. (2013), The cancer-associated FGFR4-G388R polymorphism enhances pancreatic insulin secretion and modifies the risk of diabetes, Cell Metab 17, 929-40

Gusenbauer S., Vlaicu P., and Ullrich A. (2013), HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors, Oncogene 32(33):3846-56  

Publications 2012

Oak PS., Kopp F., Thakur C., Ellwart JW., Rapp UR., Ullrich A., Wagner E., Knyazev P., and Roidl A. (2012), Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells, Int J Cancer 131,2808-2819

Bezler M., Hengstler J., and Ullrich A. (2012), Inhibition of Doxorubicin-Induced HER3-PI3K-AKT Signalling Enhances Apoptosis of Ovarian Cancer Cells, Mol. Onc. 6, 516-529

Piccolo E., Tinari N., Semeraro D., Traini S., Fichera I., Cumashi A., La Sorda R., Spinella F., Bagnato A., Lattanzio R., D’Egidio M., Di Risio A., Stampolidis P., Piantelli M., Natoli C., Ullrich A., and Iacobelli S. (2012), LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angionesis, J Mol Med 9, 83-94

Bender C., and Ullrich A. (2012) PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma cell lines. Int J of Cancer 131(2):E45-55

Publications 2011

Alokail MS, Al-Daghri NM, Al-Attas OS, Alkharfy KM, Sabico SB, and Ullrich A.(2011), Visceral obesity and inflammation markers in relation to serum prostate volume biomarkers among apparently healthy men,    Eur. J. Clin. Invest 41,987-94

Beji A.,  Horst D., Engel J., Kirchner T., and Ullrich  A. (2011), Towards the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer, Clin Cancer Res 18,956-968

Tateno T., Asa SL., Zheng L., Mayr T., Ullrich A., and Ezzat S. (2011), The FGFR4-G388R Polymorphism Promotes Mitochondrial STAT3 Serine Phosphorylation to Facilitate Pituitary Growth Hormone Cell Tumorigenesis, PLoS Genet. 7(12):e1002400

Publications 2010

Seitzer, N., Mayr, T., Streit, S. and Ullrich, A. (2010), A single nucleotide change in the mouse genome accelerates breast cancer progression, Cancer Res. 70:802-12

Chua, BT., Lim, SJ., Tham, SC., Poh, WJ., and Ullrich, A. (2010), Somatic mutation in the ACK1 ubiquitin association domain enhances oncogenic signaling through EGFR regulation in renal cancer derived cells,    Mol. Oncol. 4, 323–334

Reschke M, Ferby I, Stepniak E, Seitzer N, Horst D, Wagner EF, and Ullrich A. (2010), Mitogen-inducible gene-6 is a negative regulator of epidermal growth factor receptor signaling in hepatocytes and human hepatocellular carcinoma, Hepatology 51, 1383-90

Go to Editor View